Virtual Clinical Trials Market (By Study Design: Interventional, Observational, Expanded Access; By Indication: Oncology, Cardiovascular, CNS, Autoimmune/Inflammation, Metabolic/Endocrinology, Infectious Disease, Genitourinary, Ophthalmology, Others: By Phase: Phase I, Phase II, Phase III, Phase IV) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Virtual Clinical Trials Market 

5.1. COVID-19 Landscape: Virtual Clinical Trials Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Virtual Clinical Trials Market, By Study Design

8.1. Virtual Clinical Trials Market, by Study Design, 2022-2030

8.1.1 Interventional

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Observational

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Expanded Access

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Virtual Clinical Trials Market, By Indication

9.1. Virtual Clinical Trials Market, by Indication, 2022-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Cardiovascular

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. CNS

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Autoimmune/Inflammation

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Metabolic/Endocrinology

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Infectious Disease

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Genitourinary

9.1.7.1. Market Revenue and Forecast (2017-2030)

9.1.8. Ophthalmology

9.1.8.1. Market Revenue and Forecast (2017-2030)

9.1.9. Others

9.1.9.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Virtual Clinical Trials Market, By Phase 

10.1. Virtual Clinical Trials Market, by Phase, 2022-2030

10.1.1. Phase I

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Phase II

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Phase III

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Phase IV

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Virtual Clinical Trials Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.1.2. Market Revenue and Forecast, by Indication (2017-2030)

11.1.3. Market Revenue and Forecast, by Phase (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Indication (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Phase (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Indication (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Phase (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.2. Market Revenue and Forecast, by Indication (2017-2030)

11.2.3. Market Revenue and Forecast, by Phase (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Indication (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Phase (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Indication (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Phase (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Indication (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Phase (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Indication (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Phase (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.2. Market Revenue and Forecast, by Indication (2017-2030)

11.3.3. Market Revenue and Forecast, by Phase (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Indication (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Phase (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Indication (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Phase (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Indication (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Phase (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Indication (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Phase (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.2. Market Revenue and Forecast, by Indication (2017-2030)

11.4.3. Market Revenue and Forecast, by Phase (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Indication (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Phase (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Indication (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Phase (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Indication (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Phase (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Indication (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Phase (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.5.2. Market Revenue and Forecast, by Indication (2017-2030)

11.5.3. Market Revenue and Forecast, by Phase (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Indication (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Phase (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Study Design (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Indication (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Phase (2017-2030)

Chapter 12. Company Profiles

12.1. ICON, plc

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Parexel International Corporation

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. IQVIA

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Covance

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. PRA Health Sciences

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. LEO Innovation Lab

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Medidata

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Oracle

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. CRF Health

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Clinical Ink

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY

   USD 4500.00
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample